Investor Relations

(Security Code :4506 TSE Prime)

Pick Up

Jul. 18, 2025	Sumitomo Pharma Announces Changes in the Position Assumed by Executive Officer and Other Key Positions	Corporate
Jun. 26, 2025	Sumitomo Pharma Announces Organizational Realignment	Corporate
Jun. 26, 2025	Notice of Assignment of Assets for Key Products in the U.S. within Sumitomo Pharma Group	Corporate
Jun. 26, 2025	Matters Concerning Controlling Shareholders, Etc.	Corporate
Jun. 13, 2025	Sumitomo Pharma America Announces that Nuvisertib (TP-3654) Has Received FDA Fast Track Designation for the Treatment of Myelofibrosis（PDF/37KB）	R&D
Jun. 06, 2025	Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo’s Canadian Portfolio（PDF/175KB）	Corporate

Jul. 31, 2025	1st Quarter of FY2025 financial results announcement (planned, 3:30 p.m.)